Chylothorax

2

Review clinical trials related to Chylothorax. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax

Chylothorax is a rare but serious complication after lung cancer surgery and mediastinal lymph node dissection. This multicenter randomized trial will evaluate whether drinking 40 mL of extra-virgin olive oil 4 hours before surgery can reduce the occurrence of chylothorax after curative lung cancer resection. A total of 1,036 adults with resectable lung cancer will be assigned in a 1:1 ratio to preoperative oral olive oil or standard preoperative fasting without additional olive oil. The primary outcome is the occurrence of chylothorax within 30 days after surgery. Secondary outcomes include repeat surgery, postoperative complications, chest drainage, length of chest tube use, length of hospital stay, and the safety and tolerability of the intervention.

Participants needed: 1,036
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Sep 8, 2026Locations: 1
Eligibility criteria

Voluntary participation and willing and able to complete all study procedures. [+6]

Allergy to olive oil or any of its components. [+4]

Status: Recruiting

European Registry Study on Lymphatic Interventions

This European multicenter observational study aims to evaluate the real-world use, timing, and outcomes of lymphatic interventions in patients with congenital heart disease and/or primary lymphatic disorders. The study will examine the effectiveness of diagnostic imaging and interventional techniques, such as lymphatic embolization, in improving clinical symptoms, biomarkers, and fluid-related complications. The central question is whether early diagnosis and targeted intervention can lead to clinically meaningful improvements and reduced need for reintervention. Data collected retrospectively and prospectively from participating centers will help identify predictors of outcome, assess disease severity, and inform standardized diagnostic and therapeutic pathways across Europe.

Participants needed: 500
Trial details
Biological sex: AllType: ObservationalSponsor: Rigshospitalet, DenmarkUpdated: Jan 21, 2026Locations: 1Duration: 5 Years
Eligibility criteria

Patients of any age with a confirmed central lymphatic disorder, either in the c... [+2]

Patients with isolated peripheral lymphatic disorders not involving the central... [+3]